Mirum Pharmaceuticals Inc. (MIRM) on Monday said the primary endpoint was met in the Phase 2b portion of its AZURE-1 study evaluating brelovitug for the treatment of chronic hepatitisdelta virus (HDV).
At Week 24, brelovitug showed strong antiviral activity, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response. The primary composite endpoint—virologic response along with normalization of liver enzyme ALT—was achieved in 45% and 35% of patients in the respective dose groups, compared with none in the delayed treatment group.
The company said treatment was well tolerated, with continued reductions in viral levels and liver enzyme markers observed over 24 weeks, supporting brelovitug's potential as a standalone therapy to treat HDV.
Mirum shares closed at $91.49 on Friday, down 0.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.